An observational study in Neuroma, sponsored by Polyganics BV. Completed at 16 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-10.
Sponsored by Polyganics BV · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Neuroma with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Neuroma · United States.
Among the 25 studies in Neuroma with a site in United States, this one is one of 4 that started in 2017, is one of 7 observational ones, and was the 11th registered.
55 studies on the registry are indexed under Neuroma; 10 are open to participants now.
Browse Neuroma studies →4 of the 25 studies in Neuroma with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 22+
Medstar Health Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
University of Michigan · Sites in United States
Ages 22–75
The Methodist Hospital Research Institute · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Neuroma studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is close to the median of 67 across 15 observational studies indexed under Neuroma.
Median enrollment 19 across the 18 interventional studies, 73 across the 7 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 25 have an industry lead sponsor. The 10 most frequent:
Polyganics BV is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Polyganics BV has 2 studies filed under Neuroma — fewer than ten, so there is no comparison to draw.
2 of the studies in Neuroma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04865679Axogen CorporationTolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | 2026-12 |
| NCT06915662Massachusetts General HospitalPain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Neuroma with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PROSPECTIVE COHORT EVALUATION OF NEUROCAP® In the Treatment of symptomatic Neuroma (PROTECT Neuro)
This post-market surveillance study is conducted to provide post market surveillance information regarding long-term performance and ease of use of the Polyganics nerve capping device (NEUROCAP®) for reduction of the development of peripheral symptomatic end-neuroma.
Peripheral symptomatic end-neuroma patients indicated for surgical treatment of the neuroma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.
Device: Neurocap®
NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
Visual Analog Scale (VAS) for Pain
Subjective pain score as indicated by the patient on a scale of 1-100.
Time frame: 2 years
Recurrence of Neuroma
Recurrence of neuroma as assessed by clinical assessment by the surgeon.
Time frame: 2 years
Elliot Neuroma questionnaire
Type of pain
Time frame: 2 years
QuickDASH
Daily functioning upper limb
Time frame: 2 years
Goals questionnaire
Daily functioning lower limb
Time frame: 2 years
Type of Pain Medication
Type of pain medication currently taken
Time frame: 2 years
Amount of Pain Medication
Amount of pain medication currently taken
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2017 to primary completion in Jul 2018, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polyganics BV